大肠癌术后腹腔和静脉双路化疗的临床研究  

Clinical Study of Postoperative Intraperitoneal and Intravenous Chemotherapy for Colorectal Cancer

作　　者：熊莉 张灿珍[2] 张晓娟[2] 

机构地区：[1]湘西自治州人民医院,湖南吉首416000 [2]云南省肿瘤医院,云南昆明650118

出　　处：《实用医技杂志》2007年第19期2529-2531,共3页Journal of Practical Medical Techniques

摘　　要：目的:研究大肠癌术后腹腔灌注化疗联合静脉化疗的疗效和毒副反应。方法:40例大肠癌术后患者随机分为两组,双路化疗组行DDP腹腔灌注化疗联合LV/5-FU方案静脉化疗,静脉化疗组选择LV/5-FU+DDP方案。结果:双路化疗组2a生存率87.50﹪,3a生存率78.29﹪,均高于静脉化疗组的75.00﹪、62.50﹪(P<0.05);双路化疗组3a腹腔复发率16.67﹪,3a肝转移率20.83﹪,均低于静脉化疗组的50.00﹪、56.25﹪(P<0.05);毒副反应亦低于静脉化疗组(P<0.05)。结论:腹腔和静脉双路化疗是预防大肠癌根治术后腹腔局部复发和肝转移的有效方法,并能延长患者的生存时间。Objective To study the effect and side effect of postoperative intraperitoneal and intravenous chemotherapy for colorectal cancer. Methods 40 patients of colorectal cancer after radical resection were divided into two groups, one was double-ways chemotherapy group which was treated by intraperitoneal and intravenous chemotherapy, the other was intravenous chemotherapy group which was treaded by only intravenous chemotherapy. Results The 2-year survival rate（87.50 % ） and the 3-year survival rate（78.29 % ） of double-ways group were higher than intravenous group （75.00 % ;62.50 %, P〈0. 05 ）;the 3-year peritoneal recurrence rate（16.67 % ） and the 3-year liver metastasis rate（20.83 % ） of double-ways group were lower than intravenous group（50.00 % ; 56.25 % , P〈0.05 ） ; the side effects of double-ways group was also lower than intra venous group （P〈0.05）. Conclusion The intraperitoneal and intravenous chemotherapy has a significant advantage of preventing the peritoneal recurrence and liver metastasis for patients with colorectal cancer following radical operation,and can prolong survival time.

关 键 词：大肠癌 腹腔化疗 静脉化疗 

分 类 号：R735.34[医药卫生—肿瘤]